Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | TSC1 E636fs |
Therapy | Everolimus |
Indication/Tumor Type | bladder carcinoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TSC1 E636fs | bladder carcinoma | sensitive | Everolimus | Case Reports/Case Series | Actionable | A retrospective study of a Phase II trial correlated increased sensitivity to the mTOR inhibitor Afinitor (everolimus) with TSC1 mutations in bladder cancer patients, including one patient harboring TSC1 E636fs* who had a durable complete response (PMID: 22923433). | 22923433 |
PubMed Id | Reference Title | Details |
---|---|---|
(22923433) | Genome sequencing identifies a basis for everolimus sensitivity. | Full reference... |